{"entity":{"id":"paper-gog-0261-carcinosarcoma-powell-jco-2022","kind":"paper","name":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","aka":[],"tldr":"For uterine carcinosarcoma, the standard breast and ovarian regimen carboplatin-paclitaxel was as effective as the older, more toxic paclitaxel-ifosfamide combination, simplifying treatment of this rare aggressive cancer.","summary":"Phase 3 non-inferiority trial of 536 patients with stage I to IV, persistent or recurrent uterine carcinosarcoma (with a small ovarian carcinosarcoma cohort) randomised to paclitaxel-carboplatin or paclitaxel-ifosfamide.\n\nMedian overall survival was 37 versus 29 months (hazard ratio 0.87, non-inferior) and progression-free survival 16 versus 12 months, with more haematological toxicity but less confusion and genitourinary toxicity with carboplatin.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2022","url":"https://doi.org/10.1200/JCO.21.02050"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35007153/"}],"tags":[],"related":[],"cancers":["uterine-carcinosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","ifosfamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/JCO.21.02050","pmid":"35007153","authors":"Powell MA, Filiaci VL, Hensley ML, et al.","paperType":"rct","findings":["Median overall survival 37 vs 29 months; hazard ratio 0.87 (non-inferior).","Median progression-free survival 16 vs 12 months."],"whatItMeans":"Carboplatin-paclitaxel is the chemotherapy standard for uterine carcinosarcoma in all stages, now combined with dostarlimab in advanced disease following RUBY, which included carcinosarcoma.","caveats":["Non-inferiority design; the trend favouring carboplatin was not tested for superiority.","Adjuvant radiotherapy was not standardised."],"changedPractice":true,"participants":536},"route":"/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/","neighbours":{"cancer":[{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}